Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

Diabetologia

Volumn 47, Issue 4, 2004, Pages 622-629

  Hermansen, K ^a   Fontaine, P ^b   Kukolja, K K ^c   Peterkova, V ^d   Leth, G ^e   Gall, M A ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Varazdin General Hospital   (Croatia)

^d N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^e NOVO NORDISK A S   (Denmark)

Author keywords

Glycaemic control; Hypoglycaemia; Insulin analogues; Insulin aspart; Insulin detemir; Type 1 diabetes mellitus; Variability

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; ISOPHANE INSULIN; NEUTRAL INSULIN;

ADULT; ARTICLE; BODY WEIGHT; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION PAIN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SELF EXAMINATION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; ENDPOINT DETERMINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE;

EID: 2442678007     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1365-z     Document Type: Article

References (26)

1. The Diabetes Control and Complications Trial Research Group (1996) The absence of a glycaemic threshold for the development of long-term complications. Diabetes 45:1289-1298
2. Reichard O, Nilsson BY, Rosenqvist U (1993) The effect of long-term intensified insulin treatment in the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309
3. Wang PH, Lau J, Chalmers TC (1993) Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341:1306-1309
4. The Diabetes Control and Complications Trial Research Group (1997) Hypoglycaemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286
5. Starke A, Heinemann L, Hohlmann A, Berger M (1989) The action profiles of human NPH insulin preparations. Diabet Med 6:239-244
6. Kølendorf K, Bojsen J, Deckert T (1983) Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients. Horm Metab Res 15:274-278
7. Jehle PM, Micheler C, Jehle CR, Breitig D, Boehm BO (1999) Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 354:307-335
8. Bolli GB, Perriello G, Fanelli CG, De Feo P (1993) Nocturnal blood glucose control in type 1 diabetes mellitus. Diabetes Care 16:71-89
9. Home PD, Lindholm A, Riis A (2000) Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 17:762-771
10. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L (2000) Use of insulin aspart, a fast-acting insulin analog as the mealtime insulin in the management of patients with Type 1 diabetes. Diabetes Care 23:583-588
11. Lindholm A, McEwen J, Riis AP (1999) Improved post-prandial glycemic control with insulin aspart. Diabetes Care 22:801-805
12. Lindholm A (2002) New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 16:475-492
13. Pieber TR, Plank J, Goerzer E et al. (2002) Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetologia 45 [Suppl 2]:A254 (Abstract)
14. Vague P, Selam J-L, Skeie S et al. (2003) Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycaemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26:590-596
15. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M (2001) Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care 24:296-301
16. Russell-Jones D, Simpson R, Bolinder J, Staedes A, Stender A (2002) Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with type 1 diabetes. Diabetologia 45 [Suppl 2]:A51 (Abstract)
17. DCCT Research Group (1987) Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 33:2267-2271
18. Senn S (1994) Testing for baseline balance in clinical trials. Stat Med 13:1715-1726
19. Pickup J, Mattock M, Kerry S (2002) Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 324:705
20. Lalli C, Ciofetta M, Del Sindaco P et al. (1999) Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22:468-477
21. Madsbad S (2002) Insulin analogues: have they changed insulin treatment and improved glycaemic control? Diabetes Metab Res Rev 18:S21-S28
22. Heller S (2002) Reducing hypoglycaemia with insulin analogues. Int J Obes 26:S33-S36
23. McCrimmon RJ, Frier BM (1994) Hypoglycaemia, the most feared complication of insulin therapy. Diabetes Metab 20:503-512
24. Cryer PE (2002) Hypoglycaemia: The limiting factor in glycaemic management of type I and type II diabetes. Diabetologia 45:937-948
25. Lauritzen T, Pramming S, Gale EA, Deckert T, Binder C (1982) Absorption of isophane (NPH) insulin and its clinical implications. Br Med J 285:159-162
26. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD (1998) Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA 280:140-146